VarmX bags €32m in Series B round – European Biotechnology News
Leiden-based coagulant developer VarmX NV has closed a €32m Series B financing to push the Phase II development of VMX-C001, a venom-based modified recombinant Factor X.
New investors LSP, Ysios Capital, INKEF Capital and Lundbeckfonden...
Zoono at Cutting Edge of Reducing Risk of African Swine Flu Outbreaks
Paul Hislop, CEO and majority shareholder of ASX listed ZOONO Group Ltd (ZNO) confirmed at their AGM held in Sydney on 7th November 2109 that Zoono was at that cutting edge of...
Perth Biotech Increases Sanitiser Shipment Amid Virus Outbreak
Merlin Chew of The West Australian Monday, 10 February 2020 2:30PM
Holista Colltech chief executive Dr Rajen M with the NatShield Sanitizer. Credit: Supplied
First COVID-19 vaccine found to be safe, able to generate rapid immune response in...
Reviewed by Emily Henderson, B.Sc.May 22 2020
The first COVID-19 vaccine to reach phase 1 clinical trial has been found to be safe, well-tolerated, and able to generate an immune response against SARS-CoV-2 in humans,...
Creso Pharma’s Technological Breakthrough Set To Expand Human Health Cannabis Product Line
By BioChannel - February 10th 2020 566
By Jonathan Jackson
Creso Pharma Limited (ASX:CPH), the ASX-listed, Swiss-based innovative medical cannabis product developer, has started 2020 strongly as...
Polycistronic delivery of IL-10 and NT-3 to enhance spinal cord injury repair
Reviewed by Emily Henderson, B.Sc.Apr 18 2020
Spinal cord injury (SCI) creates a complex microenvironment that is not conducive to repair; growth factors are in short supply, whereas factors that inhibit regeneration are plentiful. In...
Phylogenomic characterization of the first genome sequences of the monkeypox virus outbreak variant
In a recent study posted to the Research Square* preprint server, researchers characterized infections caused by the monkeypox virus (MPXV).
Study: Multi-country outbreak of monkeypox virus: phylogenomic characterization and signs of microevolution. Image Credit: Kateryna...
Novel Camouflaging System Improves Delivery of Therapeutic Bacteria in Mice
Researchers from Columbia Engineering have developed a system that temporarily disguises therapeutic bacteria from the immune system and allows them to deliver drugs to tumors and kill cancer cells in mice.
Their findings are published...
New insights into SARS-CoV-2 immunity gained from natural infection
Antibody-secreting cells (ASCs) peaked at 3-4 weeks and were still being produced at 3-4 months in patients hospitalized with COVID-19, according to a study published in the peer-reviewed journal Viral Immunology.
Diane Griffin, MD, PhD,...
On/Off Pain Control Center Identified in Mouse Brain
A Duke University research team has identified a small area of the mouse brain that can profoundly control the animals’ sense of pain. Their studies found a specific subpopulation of nerve cells within the...
